[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017007654A - Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas. - Google Patents

Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.

Info

Publication number
MX2017007654A
MX2017007654A MX2017007654A MX2017007654A MX2017007654A MX 2017007654 A MX2017007654 A MX 2017007654A MX 2017007654 A MX2017007654 A MX 2017007654A MX 2017007654 A MX2017007654 A MX 2017007654A MX 2017007654 A MX2017007654 A MX 2017007654A
Authority
MX
Mexico
Prior art keywords
absorbing capacity
methods
cholesterol
accession number
probiotic strain
Prior art date
Application number
MX2017007654A
Other languages
English (en)
Inventor
Criado García Raquel
Juan Gálvez Peralta Julio
BAÑUELOS HORTIGÜELA Oscar
Isabel Sañudo Otero Ana
De La Escalera Huerso Santiago
Zarzuelo Zurita Antonio
Manuel Duarte Pérez Juan
Garach Domech Alberto
Olivares Martín Mónica
Rodríguez Nogales Alba
Original Assignee
Biosearch S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosearch S A filed Critical Biosearch S A
Publication of MX2017007654A publication Critical patent/MX2017007654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invención se refiere a una cepa probiótica seleccionada de Lactobacillus reuteri V3401 con número de acceso CECT 8605 y Bifidobacterium breve BT820 con número de acceso CECT 8606, o una variante de dicha cepa probiótica con capacidad de absorber colesterol, y a métodos y usos terapéuticos de la misma. La invención también se refiere a composiciones, composiciones farmacéuticas, piensos o productos nutricionales que comprenden una cepa probiótica seleccionada de Lactobacillus reuteri V3401 con número de acceso CECT 8605 y Bifidobacterium breve BT820 con número de acceso CECT 8606, o una variante de dicha cepa probiótica con capacidad de absorber colesterol.
MX2017007654A 2014-12-10 2015-12-10 Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas. MX2017007654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14384202.9A EP3031930A1 (en) 2014-12-10 2014-12-10 Probiotic strains having cholesterol absorbing capacity, methods and uses thereof
PCT/EP2015/079298 WO2016092032A1 (en) 2014-12-10 2015-12-10 Probiotic strains having cholesterol absorbing capacity, methods and uses thereof

Publications (1)

Publication Number Publication Date
MX2017007654A true MX2017007654A (es) 2018-05-04

Family

ID=52396401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007654A MX2017007654A (es) 2014-12-10 2015-12-10 Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.

Country Status (14)

Country Link
US (1) US11058734B2 (es)
EP (2) EP3031930A1 (es)
JP (1) JP6707087B2 (es)
CN (1) CN107438664B (es)
AU (1) AU2015359382B2 (es)
BR (1) BR112017012251A2 (es)
CA (1) CA2970602C (es)
ES (1) ES2899185T3 (es)
HU (1) HUE057081T2 (es)
MX (1) MX2017007654A (es)
PL (1) PL3230479T3 (es)
RS (1) RS62610B1 (es)
RU (1) RU2722038C2 (es)
WO (1) WO2016092032A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434427A (zh) * 2016-08-29 2017-02-22 中国疾病预防控制中心传染病预防控制所 乳酸杆菌益生菌cgmcc no.12421及在制备降脂药物中的应用
EP3522902A1 (en) * 2016-10-04 2019-08-14 Institut National de la Recherche Agronomique Use of ahr agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders
CA3065162C (en) * 2017-06-09 2023-10-17 Sami Labs Limited Hypolipidemic effects of bacillus coagulans
JP7266580B2 (ja) * 2018-03-23 2023-04-28 森永乳業株式会社 学童期以降の高血糖に起因する疾患の予防のための乳幼児用組成物
CN112646832B (zh) * 2020-12-25 2022-06-21 上海理工大学 一种调节植物乳杆菌黏附能力的方法
CN114344344B (zh) * 2022-01-05 2023-06-13 东北农业大学 罗伊氏乳杆菌在缓解高脂饮食诱导小鼠肥胖功能中的应用及含有罗伊氏乳杆菌的复合物
CN118356464A (zh) * 2023-01-19 2024-07-19 百岳特生物技术（上海）有限公司 黑青稞萃取物用于调节免疫力的用途
CN116121146B (zh) * 2023-03-09 2024-01-30 四川大学 一株产乳酸能力较强的戊糖片球菌及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3777296B2 (ja) * 2000-09-04 2006-05-24 明治製菓株式会社 乳酸菌によるコレステロールの低減若しくは除去方法
AU2001293031A1 (en) * 2000-09-25 2002-04-08 Michael Dean Gene involved in dietary sterol absorption and excretion and uses therefor
US7939061B2 (en) * 2003-02-28 2011-05-10 Micropharma Limited Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
KR100691863B1 (ko) * 2004-12-07 2007-03-13 김홍렬 비피도박테리움 비피둠의 공배양을 통한 콜레스테롤 흡수 저하방법 및 이를 이용한 콜레스테롤 저하제
JP4662443B2 (ja) * 2005-02-14 2011-03-30 明治乳業株式会社 コレステロール低減乳酸菌
JP4336992B2 (ja) * 2006-01-20 2009-09-30 日清食品ホールディングス株式会社 血中コレステロール低減作用を有する新規乳酸菌
EP2311473A1 (en) * 2009-10-09 2011-04-20 AB-Biotics Producciones Industriales De Microbiotas, S.L. Lactobacillus plantarum strains as probiotics
CN102028713A (zh) * 2010-12-12 2011-04-27 夏学德 一种用于降低血清胆固醇的益生菌制剂及其制备方法
ITMI20110792A1 (it) * 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.

Also Published As

Publication number Publication date
AU2015359382B2 (en) 2021-09-02
RU2017121227A3 (es) 2019-05-28
RU2722038C2 (ru) 2020-05-26
CN107438664B (zh) 2021-07-30
CA2970602A1 (en) 2016-06-16
PL3230479T3 (pl) 2022-05-09
US11058734B2 (en) 2021-07-13
EP3031930A1 (en) 2016-06-15
BR112017012251A2 (pt) 2018-01-30
RU2017121227A (ru) 2019-01-10
EP3230479B1 (en) 2021-10-06
ES2899185T8 (es) 2022-05-26
US20170333495A1 (en) 2017-11-23
AU2015359382A1 (en) 2017-07-27
EP3230479A1 (en) 2017-10-18
CN107438664A (zh) 2017-12-05
WO2016092032A1 (en) 2016-06-16
JP6707087B2 (ja) 2020-06-10
ES2899185T3 (es) 2022-03-10
CA2970602C (en) 2024-03-12
JP2018503367A (ja) 2018-02-08
HUE057081T2 (hu) 2022-04-28
RS62610B1 (sr) 2021-12-31

Similar Documents

Publication Publication Date Title
MX2017007654A (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.
NZ777234A (en) Compositions comprising bacterial strains
HK1226100B (zh) 雙歧桿菌乳酸亞種(bifidobacterium animalis subsp．lactis)cect 8145的新菌株及其用於治療和/或預防超重和肥胖症以及相關疾病的用途
PL3194567T3 (pl) Probiotyczne szczepy bifidobacterium adolescentis
PT3412766T (pt) Estirpe lactobacillus salivarius, composição que compreende a mesma e suas utilizações
BR112013028705A2 (pt) cepas bacterianas probióticas e composição simbiótica contendo as mesmas destinadas a alimentos para lactentes
MX2015000338A (es) Novedosa cepa de lactobacillus crispatus.
AU2019263623A8 (en) Probiotic Bifidobacterium breve strain and compositions comprising said strain
IL289610A (en) Bacterial strain Bifidobacterium bifidum, its preparations and related uses
SA519400920B1 (ar) استخدام المعززات الحيوية في علاج و/أو الوقاية من التهاب الجلد التأتبي
PH12017502042A1 (en) Dietary supplement
IT201600091033A1 (it) Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
MX2022011742A (es) Composicion nutritiva para el entorno gastrointestinal para proporcionar microbioma y perfil metabolico mejorados.
MY193248A (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
SG11201608730UA (en) Bifidobacterium breve cbt br3 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same
MX2017008700A (es) Empleo de probioticos en el incremento de la fertilidad masculina.
EP3601525C0 (en) PROBIOTIC LACTOBACILLUS CASEI STRAIN AND ITS USES
GEP20207089B (en) Histamine-producing bacterial strains and their use in cancer
EP3604497A4 (en) NEW BACTERIA OF THE GENUS BIFIDOBACTERIUM
MX2018007780A (es) Composiciones y metodos de uso de cepas novedosas de lactobacillus fermentum.
CA2913067C (fr) Utilisation d'une bacterie isolee du genre pseudoalteromonas, cyclolipopeptides et leurs utilisations
MX2020007906A (es) Composicion que comprende nuevas cepas de lactobacillus salivarius y metodo para la prevencion y el tratamiento de otitis e infecciones respiratorias de vias altas.
MX2018012312A (es) Lactobacillus rhamnosus para su uso en la preparacion de productos fermentados.
PL3489350T3 (pl) Szczep Bifidobacterium animalis AMT30 i kompozycja zawierająca szczep Bifidobacterium animalis AMT30
MY193625A (en) Probiotic composition for treatment or prevention of high blood cholesterol